chrisvoncsefalvay/vaers-outcomes huggingface dataset:
the following week after my shot I started to feel itchy and when I scratched my skin it would welt up like hives.  It would go away after awhile.  I kept feeling itchy and would have hive like welts when I scratched my skin.  I eventually went to the store and purchased Claritin to relieve the itchiness.
Patient received 2nd Moderna vaccination on 6/14/2021. Had labs drawn on 6/22 notable for AKI (Cr of 3.55 above baseline 1.6). Also had R calf pain and swelling. Presented to ER and found to have acute DVT of RLE femoral and popliteal veins. Given IVFs and AKI improved, and started on Apixaban for RLE DVT
Initial report received from healthcare professional on 16 Mar 2010: This patient was vaccinated with S-OIV FLUVIRIN, batch no: 102147P1, subcutaneously, on 16 Mar 2010. This patient inadvertently received a dose of Novartis H1N1 vaccine subcutaneously, on 16 Mar 2010. No other adverse reaction was occurred. The outcome of the event was not reported.
Second dose missed another period; random premature ovarian failure; infertility; Dose number=2; administration date=22Nov2021; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 32-year-old female patient (unknown if pregnant) received BNT162b2 (BNT162B2), on 22Nov2021 as dose 2, single (Batch/Lot number: unknown) at the age of 32 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: BNT162b2 (Dose Number: 1, Batch/Lot No: Unknown. Not available/provided to reporter at the time of report completion, Location of injection: Arm Left), administration date: 16Sep2021, when the patient was 31-year-old, for Covid-19 Immunization, reaction(s): "Missed my period after the first dose". The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 22Nov2021, outcome "unknown", described as "Dose number=2; administration date=22Nov2021"; MENSTRUAL DISORDER (disability), outcome "not recovered", described as "Second dose missed another period"; PREMATURE MENOPAUSE (disability), outcome "not recovered", described as "random premature ovarian failure"; INFERTILITY (disability), outcome "not recovered". The events "second dose missed another period", "random premature ovarian failure" and "infertility" required physician office visit. Clinical course: The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (30Dec2021) Positive, notes: Nasal Swab. Therapeutic measures were not taken as a result of menstrual disorder, premature menopause, infertility.   Patient had no allergies to medications, food, or other products. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient was not diagnosed with COVID-19, prior vaccination and since the vaccination.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
I63.9 - CVA (cerebral vascular accident) (CMS/HCC) R47.81 - Slurred speech R29.810 - Facial droop Z86.69 - History of Bell's palsy R51.9 - Headache"
Patient noticed a rash on her torso (mainly her back) and arms that appeared the Monday following her shot. She said on Thursday and today (Friday) it is on her face and fingers. She has not seen a doctor. She is going to take Benadryl and will follow up with us on how she is doing. She knows if there is any swelling in her face/throat/lips or difficulty breathing to go into the ER.
It was reported to clinic staff that the patient started vomiting shortly after receiving the COVID vaccine. She was taken to the hospital. It was reported to us that she was diagnosed with vomiting and hypertension secondary to a vaccine reaction.
pain with his teeth; Headache; Hand, foot and mouth disease: mouth sores, headache and low grade fever, body-wide itchy chicken-pox like rash on his elbows, wrists fingers, ankles, knees and buttocks and also complaining of pain with his teeth.; This spontaneous report was received from a consumer and refers to a male patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.  On 08-JUL-2023, the patient started therapy with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (rHA) (PROQUAD) injection, at a dose of 0.5 milliliters, lot #X004370, expiration date: 07-AUG-2024, administered as prophylaxis (strength, vaccination scheme, and route of administration were not provided).  On 09-JUL-2023, the patient developed a headache, fever, then body-wide itchy chickenpox-like rash on his elbows, wrists, fingers, ankles, knees, and buttocks, on 10-JUL-2023, the patient complained of pain with his teeth, progressed rash, and developed mouth sores; due the symptoms, the patient was taken to the doctor's office and was diagnosed with hand-foot-mouth virus. The outcome of the events was not reported.   The causal relationship between the events and measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) was unknown.
Three year patient received Adacel vaccine instead of Tdap vaccine/ No AE; Three year patient received Adacel vaccine instead of Tdap vaccine/ No AE; Initial information received on 18-Feb-2020 regarding an unsolicited valid non-serious case received from other health professional.  This case involves a three-year-old female patient who vaccinated with DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] instead of DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE.   Medical history, medical treatment, vaccination and family history were not provided.  On 17-Feb-2020, the patient received a 0.5 mL dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [4th dose in DTP series, lot C5556AA, expiry date: 03-Dec-2020] via an intramuscular route at the right thigh instead of DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE (TDAP) produced by unknown manufacturer for prophylactic vaccination.  It was a case of actual medication error due to wrong vaccine administered and inappropriate age at vaccine administration.  At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
fatigue, headache, body aches.  sx severe in am (day after vaccine) , improved by the evening. none by the next day.
covid-19; covid-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 48-year-old male patient received BNT162b2 (BNT162B2), on 30Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 47 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "covid-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, suspected covid-19 included Paxlovid from 22Apr2022 to 27Apr2022 for the treatment of COVID-19.  Follow-up attempts are completed. No further information is expected.
Gerneralized itching and hives on arms and legs. Took Benadryl over the counter medication. Symptoms worsened over the next 24 hours and on 10/19/2013 went to the emergency room. Diagnosis was allergic reaction, urticaria, angioedema. Was treated with oral steroids for 10 days.
Rash on buttock left area had infection oozing out of lower abdomen blisters, burning, itching, inflammation along with neuropathy in left thigh and shooting. Refer to neurologist.
1 of 3 pts immunized from the same lot exp a react; this pt had local react the size of a half dollar; no systemic reaction reported;
1 week after receiving vaccine #2, PT complained of fatigue and. Started getting lightheaded with standing  and walking. Day 11 after the vaccine  he complained of chest pain, so I took in to the ED at Hospital. His EKG, CXR, tropinin, CK,BNP were  normal but he was orthostatic by heart rate.  He followed up with Dr. and he recommended push fluids, more salt/Gatorade.  He has continued to have orthostatic tachycardia and when he walks household distances his HR goes up to 120-140. He is lightheaded with minimal exertion. Climbing one flight of stairs makes him short of breath. He has an appointment with Dr. tomorrow, 7-5 and I will request more labs and cardiology referral.  PT was in good shape and played basketball before the vaccine.
3-4-19: Itching, low grade fever, soreness 3-5-19: erythema, rash is hot to touch, 3-6-19: erythema expanded to about 6 inch diameter, still hot to touch.
Continued pain in shoulder, down to elbow (aching) sometimes sharp pain that wakes her up during night or during sudden movement.
Throwing up; Fever; Headache; Whole body aching; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (Throwing up), PYREXIA (Fever), HEADACHE (Headache) and MYALGIA (Whole body aching) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in August 2020. Concomitant products included FLUOXETINE HYDROCHLORIDE (PROZAC), BUPROPION HYDROCHLORIDE (WELLBUTRIN), GLYCOPYRRONIUM BROMIDE (ROBINUL) and TRIAMTERENE for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced VOMITING (Throwing up), PYREXIA (Fever), HEADACHE (Headache) and MYALGIA (Whole body aching). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. On 11-Mar-2021, VOMITING (Throwing up), PYREXIA (Fever) and MYALGIA (Whole body aching) had resolved. At the time of the report, HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       According to the patient, she experienced a horrible reaction, throwing up, fever, headache, and whole body aching. Treatment medication also included nausea medicine.
103 Fever and 115 resting heart rate  in evening of the day of the vaccination. 2 days later I developed reactions upon consuming food and drink (besides water). Feeling of throat closing and itchiness in the cheek and jaw area of the face indicating an allergic reaction. Symptoms are still prevalent as of today 6/24/21. I have a feeling that something is stuck in my throat/throat closing after eating most foods and consuming hard alcohol and beer. Coffee doesn?t seem to be a factor, as I originally thought the reaction was acid reflux/digestion related. Sometimes the reactions are severe enough to make breathing difficult. I have no history with food allergies and no preexisting medical conditions. My father also had the same reaction following his Janssen vaccination. He reports that he no longer has this symptom.
Developed fever & rash 6 days after shot. Rash cover all of body, fever 101, fussy, not eating. Mother called Dr. on Sun, 10/17/10, no treatment but report to health dept. 10/18 mother states rash now confined to legs, increased eating now.
29 month old given 0.5 ml of flu vaccine which should not be given until child is 36 months old.
me too; Initial information regarding an unsolicited valid non-serious social media case was received from a consumer (patient) on 09-Dec-2020.  This case involved patient with unknown demographics, who experienced Influenza (me too), while he/she received vaccine Influenza Vaccine.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient had Influenza (me too), following the administration of INFLUENZA VACCINE.  Details of laboratory data not reported.  It was not reported if the patient received a corrective treatment.  The event outcome was reported as unknown for the event, at the time of reporting.  There will be no information available on the batch number for this case.
Excruciating pain in left shoulder joint area. Reported this pain to ER on 10/18/15. Pain has continued along with decreased range of motion and high pain levels with certain actions. It is now over 3 weeks later and this continues and I can't seem to get assistance from current physician at this time as he states "these are painful vaccines". I do understand this, but this is not "normal" pain or reaction, and it should not be continuing over 3 weeks later and causing sleepless nights due to pain.
Area around injection site became inflamed and red. A few days later reaction spread farther to under side of arm. Area also looked bruised.
lost a dental bone graft due to inflammation; Hand arthritis; Cold symptoms; Headache; Tooth inflammation; FACILITATED COLLECT  This is a solicited report received from contactable reporter(s) (Consumer or other non HCP) for a sponsored program. The reporter is the patient. Other Case identifier(s): 21K-163-4153883-00 (AbbVie).  A 61 year-old female patient received bnt162b2 (BNT162B2), intramuscular (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous (Batch/Lot number: unknown) for psoriatic arthropathy. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose:1), for Covid-19 Immunization. The following information was reported: GRAFT COMPLICATION (medically significant) with onset 2021, outcome "not recovered", described as "lost a dental bone graft due to inflammation"; ARTHRITIS (non-serious) with onset 2021, outcome "not recovered", described as "Hand arthritis"; NASOPHARYNGITIS (non-serious) with onset 2021, outcome "recovered" (2021), described as "Cold symptoms"; HEADACHE (non-serious) with onset 2021, outcome "recovered" (2021), described as "Headache"; PULPITIS DENTAL (non-serious) with onset 2021, outcome "unknown", described as "Tooth inflammation". The action taken for adalimumab was unknown. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The causality as per reporter for events, lost a dental bone graft due to inflammation, hand arthritis and tooth inflammation was not reported and for the events cold symptoms and headache was possible.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information currently available,The casual association between the reported events and suspected vaccine BNT162B2 cannot be completely excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
COVID positive infection; COVID positive infection; This is a spontaneous report received from a contactable reporter (Nurse).  A 32-year-old female patient received BNT162b2 (BNT162B2), in Jan2021 as dose 1, single (batch/lot number: unknown), in Feb2021 as dose 2, single (batch/lot number: unknown) and in Mar2022 as dose 3 (booster), single (batch/lot number: unknown) at the age of 31 years for covid-19 immunization. It was reported that the vaccine facility was at a workplace clinic. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 09Jan2023, outcome "recovering" and all described as "COVID positive infection". The patient underwent the following laboratory tests and procedures: covid test/home AG test: (09Jan2023) positive, notes: nasal swab. Therapeutic measures were not taken as a result of drug ineffective, covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on available information, a possible contributory role of the subject product BNT162b2 vaccine,  cannot be excluded for suspected LOE. There is limited information provided in this report. This case will be reassessed upon receipt of follow-up information.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly
This case was reported by a healthcare professional and described the occurrence of a subject of unspecified age and gender not responding to therapy following vaccination with ENGERIX B, (GlaxoSmithKline).  On an unspecified date the subject received unspecified dose of ENGERIX 3 (unknown).  At an unspecified time after vaccination with ENGERIX B, it was noted that the subject had not responded to therapy.  At the time of reporting the outcome of the event was unspecified.
Patient took 3rd dose of Pfe/btech Covid 19 vaccine at 5 pm on 16Aug; Patient took 3rd dose of Pfe/btech Covid 19 vaccine at 5 pm on 16Aug; dizzy; burning sensation throughout the body; fell; hit her head; unconscious; fainted; This is a spontaneous report from a non-contactable consumer (patient). An elderly (over 65 years old) female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration on 16Aug2021 17:00 (Batch/Lot number was not reported) as dose 3, single for COVID-19 immunisation. Medical history included underlying heart condition. Patient was petit. The patient's concomitant medications were not reported. The patient previously received first dose and second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), on an unspecified date (Batch/Lot number was not reported) for COVID-19 immunisation.The patient took 3rd dose of Pfe/btech Covid 19 vaccine at 5 pm on 16Aug2021. At 3 am, she awoke and felt dizzy and burning sensation throughout the body and then proceeded to the bathroom and while en route fell, hit her head and fainted in Aug2021. It's unclear if fainting occurred after she hit her head or prior to. Patient fell unconscious and did not remember the whole incidence in Aug2021. Patient regained consciousness and was being evaluated by their HCPs. She appeared stable. Event took place after use of product. The outcome of the events was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Approx 15-20 min after receiving the vaccine, Pt complained of "tingling under her tongue", 5 minutes later also complained of "tingling of her lips"  No swelling of face, lips, gums, inner mouth or neck noted, no hives, no rash or redness noted. Pt given 50 mg of Benadryl.  BP 130/98 Pulse 88 and regular, breathing normal, non labored.  After 30 minutes, Pt stated her lips still feel "tingly".  BP 122/92, Pulse 92 and regular, breathing normal, non labored.  Pt called her physician.  Physician told PT to follow up with Urgent Care.
Erythema, warmth, raised to left arm around vaccine site and shooting pains down left arm and leg.
Slurred speech, crooked walking, slow thought process, unable to spell words that I've never had a problem with before.
~ 30 days after vaccine, Pt developed increasing dyspnea.  Treated with PO prednisone taper x 8 days with some improvement, however symptoms worsened off prednisone and she presented to ED on 5/3/21.  Found to have multifocal PNA with significant peripheral eosinophilia.  Treated with PO Abx and steroids again.  Repeat CT in 6/21 shows worsening multifocal PNA with peripheral eosinophilia again.  Admitted to hospital, bronchoscopy performed with results c/w chronic eosinophilic PNA.  Started on IV steroids - > PO with significant improvement in parencyhmal lung disease.
Patient was light headed and sweaty after 10 minutes getting the shot.  I was talking to him the whole time to make sure he is conscious. It seemed he lost consciousness  twice but came  back very quickly. Patient said he had lack of sleep the night before so we do not know for sure if the reaction was just because of vaccine or there are other reasons behind his reaction. By the time 911 came patient was ok and could talk and communicate well. they took him to ER for more exams.
In the middle of the night, I woke up feeling like I was freezing (like I'd relate to a fever breaking).  I had no fever and was not sweating.  I WAS shaking violently and uncontrollably for quite a while, maybe 2-3 hours.  I did NOT sense an emergency; I felt like if, like with a fever, I would just wait, I could/would ride it out.  My hand was shaking too hard to pick up my cell phone and not drop it.  Later I had a headache, and several hours later it seemed more like an hallucination.  Today I feel fine, sort of, much like after an illness.  I asm reporting because my family recommended this action.
Pfizer vaccine given as 2nd dose. Vaccine interchanged.; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Pfizer vaccine given as 2nd dose. Vaccine interchanged.) in a 20-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 050C21A) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for an unknown indication.    No Medical History information was reported.   On 19-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Sep-2021, the patient started TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (unknown route) 1 dosage form. On 17-Sep-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Pfizer vaccine given as 2nd dose. Vaccine interchanged.). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Pfizer vaccine given as 2nd dose. Vaccine interchanged.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medication information was provided. No concomitant medication information was provided.
Rash at site of KINRIX and MMR localized, no induration no cellulitis.